Shanghai, China In 2017 was created Quan Capital, which is appeared as VC. The venture was found in Asia in China. The main office of represented VC is situated in the Shanghai.
The overall number of key employees were 3.
Among the most popular portfolio startups of the fund, we may highlight ARMO BioSciences, Centrexion, Tempest Therapeutics. For fund there is no match between the country of its foundation and the country of its the most frequent investments - United States. Besides, a startup requires to be at the age of 4-5 years to receive the investment from the fund. The fund has specific favorite in a number of founders of portfolio startups. We can highlight the next thriving fund investment areas, such as Biotechnology, Mobile Apps.
The standard case for the fund is to invest in rounds with 7-8 partakers. Despite the Quan Capital, startups are often financed by OrbiMed, Kleiner Perkins, DAG Ventures. The meaningful sponsors for the fund in investment in the same round are OrbiMed, Takeda Ventures, Qiming Venture Partners. In the next rounds fund is usually obtained by EFung Capital.
The average startup value when the investment from Quan Capital is 100-500 millions dollars. The common things for fund are deals in the range of 50 - 100 millions dollars. The fund is constantly included in 2-6 investment rounds annually. This Quan Capital works on 9 percentage points more the average amount of lead investments comparing to the other organizations. The increased amount of exits for fund were in 2019. Considering the real fund results, this VC is 18 percentage points more often commits exit comparing to other organizations. The high activity for fund was in 2018.
Related Funds
Funds with similar focus
| Fund Name | Location |
| BayStartUP | Bavaria, Germany, Nuremberg |
| Beechtree Capital | New York, New York, United States |
| Binhai | China, Guangdong, Guangzhou |
| Blackstone Technology Group | Massachusetts, United States, Worcester |
| Chief Scientist | - |
| Eatable Adventures | Community of Madrid, Madrid, Spain |
| John E. Fetzer Memorial Trust | Mississippi, United States, Vicksburg |
| Liquidity Capital | New York, New York, United States |
| Millennium Network | New York, New York, United States |
| NDI Healthcare Fund | Cleveland, Ohio, United States |
| Netmarble | Seoul, Seoul-t'ukpyolsi, South Korea |
| Pablo Capital | - |
| Penny Black | New York, New York, United States |
| POMP | France, Ile-de-France, Paris |
| Shandong Best Power Investment | China, Jinan, Shandong |
| Stoic Capital | Brooklyn, New York, United States |
| Strategic Aerospace and Defence Initiative | Canada, Ontario, Ottawa |
| Weston Presidio Capital | Boston, Massachusetts, United States |
Notable deals
| Company | Industry | Round Size | Date | Investors | Location |
Avenzo Therapeutics | $150M | 26 Mar 2024 | San Diego, California, United States | ||
Adcentrx Therapeutics | $51M | 24 Apr 2023 | San Diego, California, United States | ||
Alebund Pharmaceuticals | $30M | 12 Apr 2023 | Shanghai, China | ||
Zenas BioPharma | $118M | 07 Nov 2022 | - | ||
OriginCell | $120M | 01 Aug 2022 | Zhangdian District, Shandong, China | ||
Yuanyin Bio | $43M | 20 Jun 2022 | Haidian, Beijing, China | ||
Innoforce Pharmaceuticals | $57M | 06 Dec 2021 | Hangzhou, Zhejiang, China | ||
Yuanyin Bio | $15M | 29 Nov 2021 | Haidian, Beijing, China | ||
Alebund Pharmaceuticals | $54M | 13 Sep 2021 | Shanghai, China |
– Walking Fish Therapeutics, a leader in B cell engineering, announced the close of $50M Series A financing— led by Emerson Collective, Illumina Ventures and Quan Capital— to develop B cell therapeutics for oncology, rare disease, regenerative medicine, autoimmune disease, and recombinant antibody production.
– Walking Fish Therapeutics has made critical advances in developing a platform to harness B cells’ capability to activate the immune system in the treatment of cancer, and to serve as in vivo protein factories that produce replacement proteins for deficiency diseases, regenerative proteins, and engineered antibodies.
– Interius BioTherapeutics, a Philadelphia, PA-based preclinical stage gene therapy company developing a paradigm-shifting platform for in vivo cell-specific gene delivery, raised $76m in Series A financing.
– The round was co-led by Cormorant Asset Management and Fairmount Funds, and joined by Bain Capital Life Sciences, Pfizer Ventures, RA Capital Management, Longwood Fund, Logos Capital, Osage University Partners and Quan Capital.
1. You post comments at your own choice and risk. You bear the whole responsibility,related to their substance, content and the fact of publication. We shall not bear anyliability in respect of such comments.
2. While commenting, you shall use only actual, truthful and confirmed data. In thesame time you shall not use vulgar, abusive or defamatory language as well as expresshatred or call to violence or cruelty.
3. We do not intend to delete any comments on the website unless within our “noticeand take down” procedure.
4. We can moderate comments at any time.
5. While commenting, you are under the rule of our website’s terms of use and privacypolicy.
6. We retain our right to delete any comment or any other content of the website at ourwill in case we know or suppose such content is illegal or breaches any lawful right.
Review
- No reviews are submitted yet.
Sign up and get access to full fund profile and advanced analysis.
Full teamIndustries heatmapStages heatmapGeorgaphy breakdownCoinvestorsPortfolio analysisPerformance indexesLatest highlights
Unlock all data Latest deals
| Company | Industry | Round Size | Date | Investors | Location |
Avenzo Therapeutics | $150M | 26 Mar 2024 | San Diego, California, United States | ||
Adcentrx Therapeutics | $51M | 24 Apr 2023 | San Diego, California, United States | ||
Alebund Pharmaceuticals | $30M | 12 Apr 2023 | Shanghai, China | ||
Zenas BioPharma | $118M | 07 Nov 2022 | - | ||
OriginCell | $120M | 01 Aug 2022 | Zhangdian District, Shandong, China | ||
Yuanyin Bio | $43M | 20 Jun 2022 | Haidian, Beijing, China | ||
Innoforce Pharmaceuticals | $57M | 06 Dec 2021 | Hangzhou, Zhejiang, China | ||
Yuanyin Bio | $15M | 29 Nov 2021 | Haidian, Beijing, China | ||
Alebund Pharmaceuticals | $54M | 13 Sep 2021 | Shanghai, China |
